Curasight A/S

Equities

CURAS

DK0061295797

Biotechnology & Medical Research

End-of-day quote NORDIC GROWTH MARKET Other stock markets 23:00:00 13/05/2024 BST			5-day change	1st Jan Change
9.98 ^DKK	-4.50%		-0.20%	-43.77%

04-16	Curasight A/S Announces Approval of Clinical Trial Application for Phase 2 Trial with uTRACE in Prostate Cancer Patients	CI
04-12	Curasight A/S Announces Board Changes	CI

BioStock: Curasight gets first milestone payment from Curium

February 02, 2024 at 07:46 am

The prostate cancer partnership with Curium marks the most pivotal moment for the radiopharmaceutical focused biotech company Curasight to date. Now, the company has announced a first milestone payment under the deal, for the validation of GMP manufacturing of finished product. BioStock reached out to CEO Ulrich Krasilnikoff to learn more.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/02/curasight-gets-first-milestone-payment-from-curium/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

https://news.cision.com/curasight/r/biostock--curasight-gets-first-milestone-payment-from-curium,c3920971

Latest news about Curasight A/S

Curasight A/S Announces Approval of Clinical Trial Application for Phase 2 Trial with uTRACE in Prostate Cancer Patients	04-16	CI
Curasight A/S Announces Board Changes	04-12	CI
Curasight A/S Reports Earnings Results for the Full Year Ended December 31, 2023	02-22	CI
Curasight A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-22	CI
Curasight A/S Announces Acceleration of Therapeutic Strategy to Strengthen Position as A Radiopharmaceutical Theranostic Company	02-13	CI
Curasight Gears Up for Phase II Study in Prostate Cancer	12-22	CI
Curasight A/S Submits Clinical Trial Application for Phase 2 Trial with Utrace	12-18	CI
Curasight A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-23	CI
Curasight A/S Reports Positive Preclinical Results with uTREAT[®] in lung cancer	18/10/23	CI
Curasight A/S Announces Positive Results from the Phase II Study of uTRACE in Brain Cancer Presented at the World Molecular Imaging Congress 2023 in Prague	14/09/23	CI
Curasight A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	24/08/23	CI
Curasight A/S Announces Positive Results in Upar-Pet/MR Phase II Study in Brain Cancer	29/06/23	CI
Curasight A/S Reports Positive Preclinical Results with uTREAT in Aggressive Brain Cancer (Glioblastoma)	07/06/23	CI
Curasight A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	25/05/23	CI
Curasight Secures Global License Agreement for Utrace in Prostate Cancer	11/05/23	CI
Curasight A/S Enters into an Exclusive Global License and Collaboration Agreement with Curium Inc	01/05/23	CI
Curasight A/S Reports Earnings Results for the Full Year Ended December 31, 2022	23/02/23	CI
Curasight A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23/02/23	CI
Curasight A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	24/11/22	CI
Curasight A/S Initiates Pre-Clinical Studies with uTREAT Therapy in Head and Neck Cancer and Neuroendocrine Tumors	13/10/22	CI
Curasight A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	25/08/22	CI
Curasight A/S Announces Recruitment Completes in uPAR-PET Study in Brain Cancer	30/06/22	CI
Curasight A/S Reports Earnings Results for the First Quarter Ended March 31, 2022	24/05/22	CI
Curasight A/S Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021	24/02/22	CI
Curasight A/S Expands its Strategy and Strengthen its Position as a Theranostic Company	23/02/22	CI

Chart Curasight A/S

Duration

Period

More charts

Company Profile

Curasight A/S is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (uPAR). The technology provides improved diagnosis and risk stratification in multiple cancer types.

Sector

Biotechnology & Medical Research

Calendar

22/05/2024 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CURASIGHT A/S	-43.77%	28.79M
MODERNA, INC.	+29.47%	49.18B
IQVIA HOLDINGS INC.	+0.99%	42.11B
LONZA GROUP AG	+50.47%	40.37B
CELLTRION, INC.	-5.26%	28.85B
ICON PUBLIC LIMITED COMPANY	+13.64%	26.09B
ALNYLAM PHARMACEUTICALS, INC.	-22.72%	18.71B
BIO-TECHNE CORPORATION	+8.46%	13.26B
MEDPACE HOLDINGS, INC.	+32.20%	12.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.74%	11.99B

Other Biotechnology & Medical Research